Shares of Merck & Co. Inc. MRK shed 1.31% to $115.63 Monday, on what proved to be an all-around great trading session for the ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

The Health Sciences Authority (HSA) of Singapore has approved Merck & Co’s Winrevair (sotatercept), for the treatment of ...

The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), ...

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

Merck Foundation  FASHION Awards “More Than a Mother” to address one or more of the following social issues such as: Breaking Infertility Stigma, Supporting Girl, Ending Child Marriage, Ending FGM, St ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...